<DOC>
	<DOCNO>NCT02185820</DOCNO>
	<brief_summary>This protocol phase I/II multicenter study design ass safety efficacy propose combination relapse and/or refractory Multiple Myeloma ( MM ) patient .</brief_summary>
	<brief_title>Phase I/II Study Carfilzomib , Pomalidomide Dexamethasone Relapsed And/Or Refractory Multiple Myeloma Patients ( CPD )</brief_title>
	<detailed_description>TREATMENT PERIOD Patients start salvage treatment CPd , soon screen visit pre-treatment period terminate . Patients receive 8 CPd cycle . PHASE I In phase I part study , follow dose level pomalidomide study constant dose dexamethasone carfilzomib : Level -1 Carfilzomib = 20 mg/m2 IV daily day 1 cycle 1 follow 27 mg/m2 day 8 , 15 cycle 1 , subsequent dose 27 mg/m2 IV daily day 1 , 8 , 15 follow 13-day rest period ( day 16 28 ) . Pomalidomide = 4 mg daily day 1 - 21 every 28 day . Dexamethasone = 20 mg day 1 , 8 , 15 , 22 every 28 day . Level 0 ( start dose ) Carfilzomib = 20 mg/m2 IV daily day 1 cycle 1 follow 36 mg/m2 day 8 , 15 cycle 1 , subsequent dose 36 mg/m2 IV daily day 1 , 8 , 15 follow 13-day rest period ( day 16 28 ) . Pomalidomide = 4 mg daily day 1 - 21 every 28 day . Dexamethasone = 20 mg day 1 , 8 , 15 , 22 every 28 day . Level +1 Carfilzomib = 20 mg/m2 IV daily day 1 cycle 1 follow 45 mg/ m2 day 8 , 15 cycle 1 , subsequent dose 45 mg/m2 IV daily day 1 , 8 , 15 follow 13-day rest period ( day 16 28 ) . Pomalidomide = 4 mg daily day 1 - 21 every 28 day . Dexamethasone = 20 mg day 1 , 8 , 15 , 22 every 28 day . Level +2 Carfilzomib = 20 mg/m2 IV daily day 1 cycle 1 follow 56 mg/m2 day 8 , 15 cycle 1 , subsequent dose 56 mg/m2 IV daily day 1 , 8 , 15 follow 13-day rest period ( day 16 28 ) . Pomalidomide = 4 mg daily day 1 - 21 every 28 day . Dexamethasone = 20 mg day 1 , 8 , 15 , 22 every 28 day . Patients observe first cycle therapy assessment side effect observation DLTs . Dose escalation proceed follow : 3 patient enter dose level 0 . If none 3 experience DLT , dose escalation continue . If one three patient experience DLT , three additional patient add cohort ( max 6 ) . If two three patient experience DLT give dose , MTD exceed MTD precede dose &lt; one 6 patient experienced DLT . If patient experience DLT ( 1 6 ) dose escalation continue . If 2 patient experience DLT ( 2 6 ) MTD exceed MTD previous dose &lt; 1 patient 6 experienced DLT . The phase I study end MTD define . PHASE II The phase II study start MTD define phase I study . The dose use treat patient phase II MTD define phase I study . In second part study , MTD association CPd ( absence MTD observe ) dos dose level 3 ( maximum per protocol dose ) administer total 45 consecutive patient order assess response rate clinical efficacy . THE PHASE 2 OF THE STUDY WILL START ONLY AFTER THE ANALYSIS OF THE PHASE 1 RESULTS AND THE RELEVANT STUDY REPORT . MANTEINANCE PERIOD At end 8 course , maintenance phase start . Patients receive : Carfilzomib = MTD achieve phase I study day 1 , 8 , 15 28-days cycle . Pomalidomide = 4 mg daily day 1 - 21 every 28 day . Dexamethasone = 20 mg day 1 , 8 , 15 , 22 . Patients stop PD intolerance . For maintenance period continuous assessment toxicity tolerability profile CPd combination could permit Investigators continue treatment use Pomalidomide Carfilzomib alone accord dose modification plan .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age &gt; 18 year . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Patient , investigator ( ) opinion , willing able comply protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Female patient either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male patient agree use acceptable method contraception ( i.e. , condom abstinence ) duration study . Patients primary refractory relapsed/refractory Lenalidomide . Subjects must receive least 2 consecutive cycle prior treatment include Lenalidomide alone combination . Subject must primary refractory relapsed/refractory Lenalidomide , define : 1 ) never achieve response well progressive disease ( PD ) Lenalidomidecontaining regimen ; 2 ) document disease progression within 60 day complete last myeloma Lenalidomidecontaining regimen . Both relapse and/or refractory Bortezomib naive Bortezomib patient enrol . Patient measurable disease , define follow : quantifiable serum monoclonal protein value ( generally , necessarily , ≥ 0.5 g/dL Mprotein ) , applicable , urine lightchain excretion &gt; 200 mg/24 hour . For patient oligo nonsecretory MM , require measurable plasmacytoma &gt; 2 cm determine clinical examination applicable radiograph ( i.e . MRI , CTScan ) abnormal free light chain ratio ( n.v. : 0.261.65 ) . We anticipate less 10 % patient admit study oligo nonsecretory MM free light chain order maximize interpretation benefit result . Patient Karnofsky performance status ≥60 % . Patient lifeexpectancy &gt; 3 month . Patient follow laboratory value within 14 day Baseline ( day 1 Cycle 1 , study drug administration ) : Platelet count ≥ 50 x 109/L ( ≥ 30 x 109/L myeloma involvement bone marrow &gt; 50 % ) within 14 day prior drug administration ) . Hemoglobin ≥ 8 g/dL ( 80 g/L ) within 14 day prior enrollment ( subject may receive red blood cell [ RBC ] transfusion accordance institutional guideline ) . Absolute neutrophil count ( ANC ) ≥ 1 x 109/L without use growth factor . Corrected serum calcium ≤14 mg/dL ( 3.5 mmol/L ) Alanine transaminase ( ALT ) : ≤ 3.5 x ULN . Total bilirubin : ≤ 2 x ULN . Calculated measured creatinine clearance ≥ 45 mL/min . Newly diagnose myeloma patient . Patient nonsecretory MM , unless serum free light chain present ratio abnormal . Pregnant lactating female . Major surgery within 21 day prior enrollment . Acute active infection require treatment ( systemic antibiotic , antiviral , antifungal ) within 14 day prior enrolment . Patient active infectious hepatitis type A , B C HIV . Unstable angina myocardial infarction within 4 month prior enrollment , NYHA Class III IV heart failure , uncontrolled angina , history severe coronary artery disease , severe uncontrolled ventricular arrhythmia , sick sinus syndrome , electrocardiographic evidence acute ischemia Grade 3 conduction system abnormalities unless subject pacemaker . Uncontrolled hypertension uncontrolled diabetes within 14 day prior enrollment . Significant neuropathy ( Grades 34 , Grade 2 pain ) within 14 day prior enrollment . Known history allergy Captisol ( cyclodextrin derivative use solubilize carfilzomib ) . Contraindication require concomitant drug supportive treatment , include hypersensitivity anticoagulation antiplatelet option , antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment . Subject pleural effusion require thoracentesis ascites require paracentesis within 14 day prior baseline . Any clinically significant medical disease condition , Investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent . Nonhematologic malignancy within past 3 year exception ) adequately treat basal cell carcinoma , squamous cell skin cancer , thyroid cancer ; b ) carcinoma situ cervix breast ; c ) prostate cancer Gleason Grade 6 less stable prostatespecific antigen level ; ) cancer consider cure surgical resection unlikely impact survival duration study , localize transitional cell carcinoma bladder benign tumor adrenal pancreas .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Relapsed and/or refractory</keyword>
	<keyword>CPD</keyword>
</DOC>